Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Sunshine Biopharma Inc. (SBFMW:NASDAQ), powered by AI.
Sunshine Biopharma Inc. is currently trading at $0.06. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Sunshine Biopharma Inc. on Alpha Lenz.
View Sunshine Biopharma Inc.'s valuation metrics on Alpha Lenz.
“Sunshine Biopharma Inc.'s ROE is -25.7%. Explore profitability and growth together.”
Ask for details →Sunshine Biopharma Inc. is a biotechnology company dedicated to the research, development, and commercialization of pharmaceutical products designed to tackle some of the most challenging health conditions. With a strong focus on cancer treatment, Sunshine Biopharma is at the forefront of creating innovative therapies aimed at improving patient outcomes. The company is involved in the development of both proprietary drugs and the enhancement of existing pharmaceutical compounds, seeking to address unmet medical needs in oncology and infectious diseases. Sunshine Biopharma operates in a sector characterized by high levels of research and regulatory requirements, necessitating robust scientific evaluation and clinical trials. In the financial market, the company’s performance can reflect broader trends in the biotechnology industry, particularly in terms of emerging scientific breakthroughs, regulatory approvals, and collaborations with other pharmaceutical entities. By advancing their pipeline of drug candidates, Sunshine Biopharma plays a significant role in contributing to the healthcare landscape, pushing the boundaries of traditional treatment methods and offering hope for more effective medical solutions.
“Sunshine Biopharma Inc.'s ROE is -25.7%. Explore profitability and growth together.”
Ask for details →Sunshine Biopharma Inc. (ticker: SBFMW) is a company listed on NASDAQ in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 52 employees.
The current price is $0.06 with a P/E ratio of -x and P/B of -x.
ROE is -25.68% and operating margin is -12.34%. Annual revenue is $36M.